nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.04.2009 | Original Article

In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells

verfasst von: Xiao-ling Lu, Xiao-bing Jiang, Ru-en Liu, Sheng-min Zhang

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Cytotoxic CD8⁺ T cells are key effectors in the immunotherapy of malignant and viral diseases. However, autologous T cell responses to tumor antigens presented by self-MHC are usually weak and ineffective. Allo-restricted T cells represent a potent source of tumor-specific T cells for adoptive immunotherapy. This study reports in vivo anti-melanoma efficacy of the pTRP2-specific allo-restricted CTLs expanded from the BALB/c splenocytes by multiple stimulations with aAPCs made by coating H-2K^b-Ig/pTRP2 dimeric complexes, anti-CD28 antibody, 4-1BBL molecules and CD83 molecules to cell-sized latex beads. The induced allo-restricted CTLs exhibited specific lysis against RMA-S cells pulsed with the peptide pTRP2 and H-2K^b+ melanoma cells expressing TRP2, while a murine Lewis lung carcinoma cell line 3LL could not be recognized by the CTLs. The peptide-specific activity was inhibited by anti-H-2K^b monoclonal antibody Y3. Adoptive transfer of the allo-restricted CTLs specific for malignant melanoma expanded by the aAPCs can mediate effective anti-melanoma response in vivo. These results suggested that the specific allo-restricted CTLs expanded by aAPCs coated with an MHC-Ig/peptide complex, anti-CD28 antibody, 4-1BBL and CD83 could be a potential option of specific immunotherapy for patients with malignant melanoma.

Zinkernagel RM, Doherty PC (1979) MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 27:51–177PubMedCrossRef

Germain RN, Margulies DH (1993) The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403–450PubMedCrossRef

Rammensee HG, Bevan MJ (1984) Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 308:741–744PubMedCrossRef

Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050PubMed

Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheralblood stem-cell transplantation. N Engl J Med 343:750–758PubMedCrossRef

Sadovnikova E, Stauss HJ (1996) Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci USA 93:13114–13118PubMedCrossRef

Sadovnikova E, Jopling LA, Soo KS, Stauss HJ (1998) Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 28:193–200PubMedCrossRef

Dutoit V, Guillaume P, Romero P, Cerottini JC, Valmori D (2002) Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201-donor: exploring tumor antigen allorestricted recognition. Cancer Immun 2:7PubMed

Mutis T, Blokland E, Kester M, Schrama E, Goulmy E (2002) Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood 100:547–552PubMedCrossRef

10.

Lu XL, Jiang XB, Liu RE, Zhang FC, Zhao HY (2007) Generation of Allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells. Cancer Lett 256:128–135PubMedCrossRef

11.

Savage P, Gao L, Vento K, Cowburn P, Man S, Steven N, Ogg G, McMichael A, Epenetos A, Goulmy E, Stauss HJ (2004) Use of B cell bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103:4613–4615PubMedCrossRef

12.

Bloom MB, Perry-Lalley D, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185:453–459PubMedCrossRef

13.

Schreurs MW, Eggert AA, de Boer AJ, Vissers JLM, van Hall T, Offringa R, Figdor CG, Adema GJ (2000) Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 60:6995–7001PubMed

14.

Yang Y, Fruh K, Chambers J, Waters JB, Wu L, Spies T, Peterson PA (1992) Major histocompatibility complex (MHC) encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. J Biol Chem 267:11669–11672PubMed

15.

Townsend A, Ohlen C, Bastin J, Ljunggren HG, Foster L, Karre K (1989) Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340:443–448PubMedCrossRef

16.

Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L (1994) CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67–71PubMedCrossRef

17.

Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96PubMedCrossRef

18.

Jiang XB, Lu XL, Liu RE, Zhang FC, Zhao HY (2007) HLA tetramer-based artificial antigen-presenting cells efficiently stimulate cytotoxic T lymphocytes specific for malignant glioma. Clin Cancer Res 13:7329–7334PubMedCrossRef

19.

Rees W, Bender J, Teague TK, Kedl RM, Crawford F, Marrack P, Kappler J (1999) An inverse relationship between T cell receptor affinity and antigen dose during CD4⁺ T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 96:9781–9786PubMedCrossRef

20.

Qian L, Qian GX (2002) In vivo CTL immunity can be elicited by OVA-linker-β2m fusion protein. Acta Biochim Biophys Sin 34:547–552PubMed

21.

Hammerling GJ, Rusch E, Tada N, Kimura S, Hammerling U (1982) Localization of allodeterminants on H-2K^b antigens determined with monoclonal antibodies and H-2 mutant mice. Proc Natl Acad Sci USA 79:4737–4741PubMedCrossRef

22.

Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al (1988) Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676–1680PubMed

23.

Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ (1995) Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13:1939–1949PubMed

24.

Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J, Meehan J, Mauri F (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 92:8078–8082PubMedCrossRef

25.

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMedCrossRef

26.

Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ (1999) Allo-major histocompatibility complex—restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood 94:2999–3006PubMed

27.

Ogg GS, Jin X, Bonhoeffer S, Rod Dunbar P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ (1998) Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103–2106PubMedCrossRef

28.

Busch DH, Pilip IM, Vijh S, Pamer EG (1998) Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 8:353–362PubMedCrossRef

29.

Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Liénard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641–1650PubMedCrossRef

30.

Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P, Cerundolo V (1998) Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 8:413–416PubMedCrossRef

31.

Levine BL, Cotte J, Small CC, Carroll RG, Riley JL, Bernstein WB, Van Epps DE, Hardwick RA, June CH (1998) Large-scale production of CD4⁺ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 7:437–448PubMed

32.

Deeths MJ, Mescher MF (1997) B7–1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur J Immunol 27:598–608PubMedCrossRef

33.

Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP (2003) Ex vivo induction and expansion of antigenspecific cytotoxic T cells by HLA–Ig-coated artificial antigen-presenting cells. Nat Med 9:619–625PubMedCrossRef

34.

Zemon H (2003) An artificial solution for adoptive immunotherapy. Trends Biotechnol 21:418–420PubMedCrossRef

35.

Cheuk AT, Mufti GJ, Guinn BA (2004) Role of 4–1BB:4–1BB ligand in cancer immunotherapy. Cancer Gene Ther 11:215–226PubMedCrossRef

36.

Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Joseph Brown T, Emswiler J, Raecho H, Larsen CP, Pearson TC, Ledbetter JA, Aruffo A, Mittler RS (1997) 4–1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 186:47–55PubMedCrossRef

37.

Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH (2001) 4–1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 167:1313–1324PubMed

38.

Laderach D, Movassagh M, Johnson A, Mittler RS, Galy A (2002) 4–1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol 14:1155–1167PubMedCrossRef

39.

Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S (2001) Divergent effects of 4–1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 61:2031–2037PubMed

40.

Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R (2003) Provision of 4–1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 170:2912–2922PubMed

41.

Yan X, Johnson BD, Orentas RJ (2004) Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4–1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology 112:105–116PubMedCrossRef

42.

Bukczynski J, Wen T, Watts TH (2003) Costimulation of human CD28-T cells by 4–1BB ligand. Eur J Immunol 33:446–454PubMedCrossRef

43.

Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L (1998) Amplification of tumor immunity by gene transfer of the co-stimulatory 4–1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 28:1116–1121PubMedCrossRef

44.

Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH (2001) 4–1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell Immunol 210:56–65PubMedCrossRef

45.

Hirano N, Butler MO, Xia ZN, Ansén S, von Bergwelt-Baildon MS, Neuberg D, Freeman GJ, Nadler LM (2006) Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107:1528–1536PubMedCrossRef

Titel: In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells
verfasst von: Xiao-ling Lu
Xiao-bing Jiang
Ru-en Liu
Sheng-min Zhang
Publikationsdatum: 01.04.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 4/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0573-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma

High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse

A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes

Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie